Predicta Biosciences and CIMA LAB Diagnostics Announce Agreement to Advance Ultrasensitive Blood-Based Diagnostics for Multiple Myeloma and Other Hematological Malignancies

Key Takeaways

• Predicta and CIMA LAB launch combined flow cytometry and GenoPredicta service
• Service targets academic and biopharma customers across Spain and EU
• GenoPredicta assay enables single‑cell genome profiling of rare tumor clones
• Partnership aims to accelerate MRD detection and precision oncology in blood cancers
• Dr. Paiva will present platform data at EHA 2026 Congress in Stockholm

Pulse Analysis

Blood‑cancer diagnostics are undergoing a rapid transformation as clinicians demand more precise tools to detect minimal residual disease (MRD) and guide therapy choices. Traditional flow cytometry offers phenotypic insight, while next‑generation sequencing provides genomic depth, yet few solutions integrate both at the single‑cell level. In Europe, the market for advanced hematologic diagnostics is projected to grow double‑digit percentages, driven by rising incidence of multiple myeloma and the expanding pipeline of immunotherapies that require robust companion diagnostics.

The GenoPredicta assay, central to the new Predicta‑CIMA LAB offering, leverages ultra‑sensitive liquid‑biopsy technology to sequence the entire genome of individual cancer cells circulating in blood. By coupling this with CIMA LAB’s high‑throughput flow cytometry, the service can both quantify rare tumor clones and map their genetic alterations, delivering actionable data for clinicians and researchers. This dual‑modal approach improves MRD detection limits, shortens turnaround times, and supports the identification of resistance mechanisms that inform next‑line treatment decisions, especially in multiple myeloma where genomic heterogeneity drives therapeutic outcomes.

Strategically, the partnership positions both companies as key players in the European precision‑oncology ecosystem. Offering the combined service across Spain and the EU taps into a network of academic hospitals and biopharma sponsors eager for validated biomarkers to accelerate trial enrollment and regulatory submissions. The upcoming presentation at the EHA 2026 Congress will further validate the platform’s clinical relevance, potentially spurring additional collaborations and investment in single‑cell diagnostics. As healthcare systems prioritize value‑based care, such integrated solutions are likely to become standard for blood‑cancer management, shaping the future of oncology diagnostics.